In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach

A major challenge remaining in drug design efforts towards protein kinase is due to the development of drug resistance initiated by the missense mutations in the kinase catalytic domain. Gain or loss of function mutations in the REarranged during Transfection (RET) tyrosine kinase gene have been ass...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular bioSystems 2014-01, Vol.10 (3), p.421-436
Hauptverfasser: George Priya Doss, C, Rajith, B, Chakraboty, Chiranjib, Balaji, V, Magesh, R, Gowthami, B, Menon, Sneha, Swati, M, Trivedi, Manjari, Paul, Jasmine, Vasan, Richa, Das, Maitreya
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 436
container_issue 3
container_start_page 421
container_title Molecular bioSystems
container_volume 10
creator George Priya Doss, C
Rajith, B
Chakraboty, Chiranjib
Balaji, V
Magesh, R
Gowthami, B
Menon, Sneha
Swati, M
Trivedi, Manjari
Paul, Jasmine
Vasan, Richa
Das, Maitreya
description A major challenge remaining in drug design efforts towards protein kinase is due to the development of drug resistance initiated by the missense mutations in the kinase catalytic domain. Gain or loss of function mutations in the REarranged during Transfection (RET) tyrosine kinase gene have been associated with the development of a wide range of human associated cancers and Hirschsprung's disease. However, to what extent these mutations might affect bio-molecular functions remains unclear. In this article, the functionally significant mutations in RET were screened with the aid of various sequence and structure based in silico prediction methods. We mapped the deleterious mutants, modelled mutant proteins and deciphered the impact of mutations on drug binding mechanisms in the RET crystal structure of PDB ID: with the potential inhibitor vandetanib by docking analysis. Furthermore, molecular dynamics simulations were undertaken to understand the mechanistic action of cancer associated mutations in altering the protein kinase structure, dynamics, and stability. According to our results, the overall effect of V804M, M918T and S922Y were destabilizing and mostly alter the electrostatic component of the binding energy. Specifically, the mutation of gatekeeper residue valine 804 present in the ATP binding pocket affects the protein stability and confers resistance to the drug vandetanib, which was consistent with previously published experimental results. Overall, our findings may provide useful structural insights for in-depth understanding of the molecular mechanism underlying RET mutation and developing effective drugs.
doi_str_mv 10.1039/c3mb70427k
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1499117538</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1499117538</sourcerecordid><originalsourceid>FETCH-LOGICAL-c394t-f11c4887a8043c163ee4928fd8441af0026f23baa87147608dbd46f23da19d283</originalsourceid><addsrcrecordid>eNo9UMtOwzAQtBCIlsKFD0A-IqSAX02cI1QFKoqQUJG4RY7ttKaJXezk0E_gr3FK6Wlnd2dntAPAJUa3GNH8TtKmzBAj2foIDHHGSELQGB8fcPo5AGchfCFEOcPoFAwIozTNUzoEPzMLg6mNdHDjXRWRXUJhFQyt72TbeVFDY4NZrtoAXQUbE4K2QcOma0VrnA1xDd-ni_681RGvjRVxr1wjYlduYeNqLbtaeKi2VjRGhp2BcnK9M9vESyFX5-CkEnXQF_s6Ah-P08XkOZm_Pc0m9_NE0py1SYWxZJxngiNGJU6p1iwnvFKcMSwqhEhaEVoKwTPMshRxVSrWj5TAuSKcjsD1n260_e50aIv4k9R1Lax2XSgwy3OMszHtqTd_VOldCF5XxcabRvhtgVHRR19M6OvDLvqXSL7a63Zlo9WB-p81_QUc7IDm</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1499117538</pqid></control><display><type>article</type><title>In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach</title><source>MEDLINE</source><source>Royal Society Of Chemistry Journals 2008-</source><source>Alma/SFX Local Collection</source><creator>George Priya Doss, C ; Rajith, B ; Chakraboty, Chiranjib ; Balaji, V ; Magesh, R ; Gowthami, B ; Menon, Sneha ; Swati, M ; Trivedi, Manjari ; Paul, Jasmine ; Vasan, Richa ; Das, Maitreya</creator><creatorcontrib>George Priya Doss, C ; Rajith, B ; Chakraboty, Chiranjib ; Balaji, V ; Magesh, R ; Gowthami, B ; Menon, Sneha ; Swati, M ; Trivedi, Manjari ; Paul, Jasmine ; Vasan, Richa ; Das, Maitreya</creatorcontrib><description>A major challenge remaining in drug design efforts towards protein kinase is due to the development of drug resistance initiated by the missense mutations in the kinase catalytic domain. Gain or loss of function mutations in the REarranged during Transfection (RET) tyrosine kinase gene have been associated with the development of a wide range of human associated cancers and Hirschsprung's disease. However, to what extent these mutations might affect bio-molecular functions remains unclear. In this article, the functionally significant mutations in RET were screened with the aid of various sequence and structure based in silico prediction methods. We mapped the deleterious mutants, modelled mutant proteins and deciphered the impact of mutations on drug binding mechanisms in the RET crystal structure of PDB ID: with the potential inhibitor vandetanib by docking analysis. Furthermore, molecular dynamics simulations were undertaken to understand the mechanistic action of cancer associated mutations in altering the protein kinase structure, dynamics, and stability. According to our results, the overall effect of V804M, M918T and S922Y were destabilizing and mostly alter the electrostatic component of the binding energy. Specifically, the mutation of gatekeeper residue valine 804 present in the ATP binding pocket affects the protein stability and confers resistance to the drug vandetanib, which was consistent with previously published experimental results. Overall, our findings may provide useful structural insights for in-depth understanding of the molecular mechanism underlying RET mutation and developing effective drugs.</description><identifier>ISSN: 1742-206X</identifier><identifier>EISSN: 1742-2051</identifier><identifier>DOI: 10.1039/c3mb70427k</identifier><identifier>PMID: 24336963</identifier><language>eng</language><publisher>England</publisher><subject>Amino Acid Substitution ; Computer Simulation ; Humans ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Mutation, Missense ; Open Reading Frames ; Polymorphism, Single Nucleotide ; Protein Binding ; Protein Conformation ; Protein Interaction Domains and Motifs - genetics ; Protein Kinase Inhibitors - chemistry ; Protein Kinase Inhibitors - metabolism ; Protein Processing, Post-Translational ; Proto-Oncogene Proteins c-ret - antagonists &amp; inhibitors ; Proto-Oncogene Proteins c-ret - chemistry ; Proto-Oncogene Proteins c-ret - genetics ; Proto-Oncogene Proteins c-ret - pharmacology ; Reproducibility of Results</subject><ispartof>Molecular bioSystems, 2014-01, Vol.10 (3), p.421-436</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c394t-f11c4887a8043c163ee4928fd8441af0026f23baa87147608dbd46f23da19d283</citedby><cites>FETCH-LOGICAL-c394t-f11c4887a8043c163ee4928fd8441af0026f23baa87147608dbd46f23da19d283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24336963$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>George Priya Doss, C</creatorcontrib><creatorcontrib>Rajith, B</creatorcontrib><creatorcontrib>Chakraboty, Chiranjib</creatorcontrib><creatorcontrib>Balaji, V</creatorcontrib><creatorcontrib>Magesh, R</creatorcontrib><creatorcontrib>Gowthami, B</creatorcontrib><creatorcontrib>Menon, Sneha</creatorcontrib><creatorcontrib>Swati, M</creatorcontrib><creatorcontrib>Trivedi, Manjari</creatorcontrib><creatorcontrib>Paul, Jasmine</creatorcontrib><creatorcontrib>Vasan, Richa</creatorcontrib><creatorcontrib>Das, Maitreya</creatorcontrib><title>In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach</title><title>Molecular bioSystems</title><addtitle>Mol Biosyst</addtitle><description>A major challenge remaining in drug design efforts towards protein kinase is due to the development of drug resistance initiated by the missense mutations in the kinase catalytic domain. Gain or loss of function mutations in the REarranged during Transfection (RET) tyrosine kinase gene have been associated with the development of a wide range of human associated cancers and Hirschsprung's disease. However, to what extent these mutations might affect bio-molecular functions remains unclear. In this article, the functionally significant mutations in RET were screened with the aid of various sequence and structure based in silico prediction methods. We mapped the deleterious mutants, modelled mutant proteins and deciphered the impact of mutations on drug binding mechanisms in the RET crystal structure of PDB ID: with the potential inhibitor vandetanib by docking analysis. Furthermore, molecular dynamics simulations were undertaken to understand the mechanistic action of cancer associated mutations in altering the protein kinase structure, dynamics, and stability. According to our results, the overall effect of V804M, M918T and S922Y were destabilizing and mostly alter the electrostatic component of the binding energy. Specifically, the mutation of gatekeeper residue valine 804 present in the ATP binding pocket affects the protein stability and confers resistance to the drug vandetanib, which was consistent with previously published experimental results. Overall, our findings may provide useful structural insights for in-depth understanding of the molecular mechanism underlying RET mutation and developing effective drugs.</description><subject>Amino Acid Substitution</subject><subject>Computer Simulation</subject><subject>Humans</subject><subject>Molecular Docking Simulation</subject><subject>Molecular Dynamics Simulation</subject><subject>Mutation, Missense</subject><subject>Open Reading Frames</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Protein Binding</subject><subject>Protein Conformation</subject><subject>Protein Interaction Domains and Motifs - genetics</subject><subject>Protein Kinase Inhibitors - chemistry</subject><subject>Protein Kinase Inhibitors - metabolism</subject><subject>Protein Processing, Post-Translational</subject><subject>Proto-Oncogene Proteins c-ret - antagonists &amp; inhibitors</subject><subject>Proto-Oncogene Proteins c-ret - chemistry</subject><subject>Proto-Oncogene Proteins c-ret - genetics</subject><subject>Proto-Oncogene Proteins c-ret - pharmacology</subject><subject>Reproducibility of Results</subject><issn>1742-206X</issn><issn>1742-2051</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9UMtOwzAQtBCIlsKFD0A-IqSAX02cI1QFKoqQUJG4RY7ttKaJXezk0E_gr3FK6Wlnd2dntAPAJUa3GNH8TtKmzBAj2foIDHHGSELQGB8fcPo5AGchfCFEOcPoFAwIozTNUzoEPzMLg6mNdHDjXRWRXUJhFQyt72TbeVFDY4NZrtoAXQUbE4K2QcOma0VrnA1xDd-ni_681RGvjRVxr1wjYlduYeNqLbtaeKi2VjRGhp2BcnK9M9vESyFX5-CkEnXQF_s6Ah-P08XkOZm_Pc0m9_NE0py1SYWxZJxngiNGJU6p1iwnvFKcMSwqhEhaEVoKwTPMshRxVSrWj5TAuSKcjsD1n260_e50aIv4k9R1Lax2XSgwy3OMszHtqTd_VOldCF5XxcabRvhtgVHRR19M6OvDLvqXSL7a63Zlo9WB-p81_QUc7IDm</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>George Priya Doss, C</creator><creator>Rajith, B</creator><creator>Chakraboty, Chiranjib</creator><creator>Balaji, V</creator><creator>Magesh, R</creator><creator>Gowthami, B</creator><creator>Menon, Sneha</creator><creator>Swati, M</creator><creator>Trivedi, Manjari</creator><creator>Paul, Jasmine</creator><creator>Vasan, Richa</creator><creator>Das, Maitreya</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140101</creationdate><title>In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach</title><author>George Priya Doss, C ; Rajith, B ; Chakraboty, Chiranjib ; Balaji, V ; Magesh, R ; Gowthami, B ; Menon, Sneha ; Swati, M ; Trivedi, Manjari ; Paul, Jasmine ; Vasan, Richa ; Das, Maitreya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c394t-f11c4887a8043c163ee4928fd8441af0026f23baa87147608dbd46f23da19d283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Amino Acid Substitution</topic><topic>Computer Simulation</topic><topic>Humans</topic><topic>Molecular Docking Simulation</topic><topic>Molecular Dynamics Simulation</topic><topic>Mutation, Missense</topic><topic>Open Reading Frames</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Protein Binding</topic><topic>Protein Conformation</topic><topic>Protein Interaction Domains and Motifs - genetics</topic><topic>Protein Kinase Inhibitors - chemistry</topic><topic>Protein Kinase Inhibitors - metabolism</topic><topic>Protein Processing, Post-Translational</topic><topic>Proto-Oncogene Proteins c-ret - antagonists &amp; inhibitors</topic><topic>Proto-Oncogene Proteins c-ret - chemistry</topic><topic>Proto-Oncogene Proteins c-ret - genetics</topic><topic>Proto-Oncogene Proteins c-ret - pharmacology</topic><topic>Reproducibility of Results</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>George Priya Doss, C</creatorcontrib><creatorcontrib>Rajith, B</creatorcontrib><creatorcontrib>Chakraboty, Chiranjib</creatorcontrib><creatorcontrib>Balaji, V</creatorcontrib><creatorcontrib>Magesh, R</creatorcontrib><creatorcontrib>Gowthami, B</creatorcontrib><creatorcontrib>Menon, Sneha</creatorcontrib><creatorcontrib>Swati, M</creatorcontrib><creatorcontrib>Trivedi, Manjari</creatorcontrib><creatorcontrib>Paul, Jasmine</creatorcontrib><creatorcontrib>Vasan, Richa</creatorcontrib><creatorcontrib>Das, Maitreya</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular bioSystems</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>George Priya Doss, C</au><au>Rajith, B</au><au>Chakraboty, Chiranjib</au><au>Balaji, V</au><au>Magesh, R</au><au>Gowthami, B</au><au>Menon, Sneha</au><au>Swati, M</au><au>Trivedi, Manjari</au><au>Paul, Jasmine</au><au>Vasan, Richa</au><au>Das, Maitreya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach</atitle><jtitle>Molecular bioSystems</jtitle><addtitle>Mol Biosyst</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>10</volume><issue>3</issue><spage>421</spage><epage>436</epage><pages>421-436</pages><issn>1742-206X</issn><eissn>1742-2051</eissn><abstract>A major challenge remaining in drug design efforts towards protein kinase is due to the development of drug resistance initiated by the missense mutations in the kinase catalytic domain. Gain or loss of function mutations in the REarranged during Transfection (RET) tyrosine kinase gene have been associated with the development of a wide range of human associated cancers and Hirschsprung's disease. However, to what extent these mutations might affect bio-molecular functions remains unclear. In this article, the functionally significant mutations in RET were screened with the aid of various sequence and structure based in silico prediction methods. We mapped the deleterious mutants, modelled mutant proteins and deciphered the impact of mutations on drug binding mechanisms in the RET crystal structure of PDB ID: with the potential inhibitor vandetanib by docking analysis. Furthermore, molecular dynamics simulations were undertaken to understand the mechanistic action of cancer associated mutations in altering the protein kinase structure, dynamics, and stability. According to our results, the overall effect of V804M, M918T and S922Y were destabilizing and mostly alter the electrostatic component of the binding energy. Specifically, the mutation of gatekeeper residue valine 804 present in the ATP binding pocket affects the protein stability and confers resistance to the drug vandetanib, which was consistent with previously published experimental results. Overall, our findings may provide useful structural insights for in-depth understanding of the molecular mechanism underlying RET mutation and developing effective drugs.</abstract><cop>England</cop><pmid>24336963</pmid><doi>10.1039/c3mb70427k</doi><tpages>16</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1742-206X
ispartof Molecular bioSystems, 2014-01, Vol.10 (3), p.421-436
issn 1742-206X
1742-2051
language eng
recordid cdi_proquest_miscellaneous_1499117538
source MEDLINE; Royal Society Of Chemistry Journals 2008-; Alma/SFX Local Collection
subjects Amino Acid Substitution
Computer Simulation
Humans
Molecular Docking Simulation
Molecular Dynamics Simulation
Mutation, Missense
Open Reading Frames
Polymorphism, Single Nucleotide
Protein Binding
Protein Conformation
Protein Interaction Domains and Motifs - genetics
Protein Kinase Inhibitors - chemistry
Protein Kinase Inhibitors - metabolism
Protein Processing, Post-Translational
Proto-Oncogene Proteins c-ret - antagonists & inhibitors
Proto-Oncogene Proteins c-ret - chemistry
Proto-Oncogene Proteins c-ret - genetics
Proto-Oncogene Proteins c-ret - pharmacology
Reproducibility of Results
title In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T02%3A05%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20silico%20profiling%20and%20structural%20insights%20of%20missense%20mutations%20in%20RET%20protein%20kinase%20domain%20by%20molecular%20dynamics%20and%20docking%20approach&rft.jtitle=Molecular%20bioSystems&rft.au=George%20Priya%20Doss,%20C&rft.date=2014-01-01&rft.volume=10&rft.issue=3&rft.spage=421&rft.epage=436&rft.pages=421-436&rft.issn=1742-206X&rft.eissn=1742-2051&rft_id=info:doi/10.1039/c3mb70427k&rft_dat=%3Cproquest_cross%3E1499117538%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1499117538&rft_id=info:pmid/24336963&rfr_iscdi=true